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Background: There are case reports and small series in the literature relating to the use of medicinal leeches by plastic surgeons;
however, larger series from individual units are rare. The aim of this article is to present a comprehensive 4-year case series of the use of
medicinal leeches, discuss the current evidence regarding indications, risks, and beneﬁts and highlight the recent updates regarding leech
speciation. Methods: Patients prescribed leeches in a 4-year period (July 2004–2008) were collated from hospital pharmacy records (N 5
35). The number of leeches used, demographic, clinical, and microbiological details were retrospectively analyzed. Results: Thirty-ﬁve
patients were treated with leeches. The age range was 2 to 98 years (mean 5 49.3). Leeches were most commonly used for venous con-
gestion in pedicled ﬂaps and replantations. Blood transfusions were necessary in 12 cases (34%) [mean 5 2.8 units, range 2–5 units].
Our infection rate was 20% (7/35) including ﬁve infections with Aeromonas spp. (14.2%). The proportion of patients becoming infected after
leech therapy was signiﬁcantly greater in the group of patients that did not receive prophylactic antibiotic treatment (Fisher’s Exact test
P 5 0.0005). In total, 14 cases (40%) were salvaged in entirety, in 7 cases 80% or more, in 2 cases 50 to 79%, and in 1 case less than
50% of the tissues were salvaged. In 11 cases (31%), the tissues were totally lost. Conclusion: Our study highlights both the beneﬁts and
the risks to patients in selected clinical situations and also the potential risks. The routine use of antibiotic prophylaxis is supported. In
view of the emerging evidence that Hirudo verbana are now used as standard leech therapy, and the primary pathogen is Aeromonas
veronii, until a large prospective multicenter study is published, large series of patients treated with leeches should be reported. VC 2011
Wiley-Liss, Inc. Microsurgery 31:281–287, 2011.
Medicinal leech therapy is currently drawing both high-
proﬁle public and scientiﬁc attention as novel indications
are explored for this ancient treatment.1 The early success
of leech therapy in plastic and reconstructive surgery2
and, more recently, its effectiveness in treating chronic
pain syndromes associated with degenerative diseases3
have helped leech therapy gain acceptance in modern
clinical medicine.4 The Food and Drug Administration of
the United States only recently approved the use of the
leech as a medical device.5 The medicinal leech, Hirudo
medicinalis, is protected internationally by its listing on
appendix II of the Convention on International Trade in
Endangered Species of Wild Fauna and Flora and in the
United Kingdom speciﬁcally under Schedule 5 of the
Wildlife and Countryside Act 1981. Most commercial
suppliers still market medicinal leeches as H. medicinalis;
however, a recent study revealed that many leeches sold
were genetically distinct from H. medicinalis and identi-
ﬁed as H. verbana.6 The predominance of H. verbana is
likely due to overharvesting of H. medicinalis in the 19th
century at the peak of their popularity and the loss of
wetlands.
These two different types of leech can be distin-
guished based on differences in color patterns on their
dorsal and ventral body surfaces. Some authors are
encouraging the use of ‘‘DNA Barcodes’’ such as cyto-
chrome oxidase I (COI) gene sequences to reveal genetic
variations in different types of leeches7 as there can be a
wide variation in physical appearance. Clariﬁcation of
these differences with regard to medical or microbiologi-
cal differences will continue over the coming years.
Early attempts to characterize the digestive tract
microbiota were limited by their purely culture-based
approach. It is now widely recognized that around 99%
of microbes are presently unculturable.8 Recent studies
have indicated that differences exist in the microbial
communities of Hirudo verbana and Hirudo orientalis.9,10
The microbial community of Hirudo medicinalis is
currently under investigation with similar advanced tech-
niques. Current studies are ongoing to elucidate the
differences between the anticoagulant proﬁles of different
Hirudo species.11
The use of leeches by plastic surgeons to aid salvage
of compromised microvascular free-tissue transfers,12,13
venously congested digits,14–16 nipples,17 ears,18 lips,19
nasal tips,20 and even the penis 21 has been reported.
There are several case reports and small series in the
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literature relating to the use of medicinal leeches in plas-
tic surgery; however, larger series from individual units
with clinical analysis are rare.22 In this article, we present
a comprehensive 4-year case series of the use of medici-
nal leeches in a plastic surgery centre and discuss the
current thinking with regard to indications, risks, and
beneﬁts.
METHODS
The hospital numbers and dates of birth of all patients
prescribed leeches in the 4-year period (July 2004–July
2008) were collated from hospital pharmacy records
(N 5 35). Using this information, the hospital notes were
retrieved and both demographic and clinical details were
retrospectively analyzed. Using the patients’ hospital
numbers, the medical notes and microbiology database
were accessed, and all transfusion requirements, swab
results, and antibiotic treatments for the ‘‘leech episode’’
were documented. The total number of leeches used over
the same 4-year period (July 2004–July 2008) was also
collated from pharmacy records. From this data, the total
ﬁnancial cost per year was calculated.
The proportion of patients becoming infected as a result
of leech therapy was compared between the group of
patients that did not receive prophylactic antibiotic treatment
and the group that did. A two-sided P value was calculated
using Fisher’s test with GraphPad prism software.
RESULTS
Our study group included 35 patients treated with
leeches between July 2004 and July 2008. The age range
was 2 to 98 years (mean 5 49.3). Seventeen patients (49%)
were females, and the remaining 18 (51%) were male. There
was a wide range of indications for treatment (See Fig. 1),
with leeches most commonly used for venous congestion in
cutaneous pedicled ﬂaps and replantations. Treatment with
leeches was started within 48 hours in 32/35 cases (See Fig.
2a) and only once was it started on day 4. None of the
patients included in the study underwent surgical re-explora-
tion for venous congestion and, no venous supercharging
procedures were performed before leech therapy. The aver-
age length of leech treatment was 5.6 days (range 1–13
days) (See Fig. 2b). Blood transfusions were necessary in
12 cases (34%) [mean 5 2.8, range 2–5 units] (See Fig. 2c).
In our series, we encountered an infection rate of 20% (7/
35) including ﬁve infections with Aeromonas hydrophila
(14.2%). Of note, all ﬁve isolates of Aeromonas were sensi-
tive to ciproﬂoxacin. Antibiotic prophylaxis was highly vari-
able depending on the consultant in charge. Only 16 of 35
patients (46%) received antibiotic prophylaxis (4 co-amoxi-
clav, 6 ciproﬂoxacin, 3 co-amoxiclav and ciproﬂoxacin, 1
metronidazole and co-amoxiclav, 1 cefuroxime, and 1 ﬂu-
cloxacillin and phenoxymethylpenicillin). The proportion of
patients becoming infected after leech therapy was signiﬁ-
cantly greater in the group of patients that did not receive a
prophylactic antibiotic treatment compared with the group
of patients who did receive antibiotic prophylaxis (26% vs.
12.5%, Fisher’s exact test P 5 0.0005). Of the seven
infected cases, one case of Pseudomonas spp. infection was
successfully treated with ciproﬂoxacin resulting in 80% sal-
vage, one infection with methicillin-resistant Staphylococ-
cus aureus resulted in 100% ﬂap loss, two cases of infection
due to Aeromonas hydrophila were successfully treated with
ciproﬂoxacin resulting in a 100% salvage rate, one infection
with Aeromonas hydrophila was treated with augmentin
resulting in 90% salvage, and two cases of Aeromonas
infection contributed to complete ﬂap loss. Our infection
rate with Aeromonas spp. was 14.2% (5/35), with a salvage
rate of 60% (3/5). The identiﬁcation of the wound isolates
was performed in a clinical diagnostic laboratory. Because
of the difﬁculties of identifying Aeromonads and the inac-
curacies of commercial kits to identify especially environ-
mental isolates, these identiﬁcations may not be accurate
but reﬂect the information given to the treating physicians.
In total following leech therapy, 14 cases (40%) were
salvaged in entirety; in 7 cases, 80% or more of the
tissue was salvaged; in 2 cases, 50 to 79% of the ﬂap
was salvaged; in one case, more than 50% of the ﬂap
was lost, and, in 11 cases (31%), the tissues were totally
lost (See Fig. 2d).
In the management of congested replanted digits, we
salvaged 7 of 10 cases (70%) in our series (See Table 1).
Additionally, we were able to salvage >90% of the ﬂap sur-
face area in 77% of our cutaneous pedicled ﬂaps, which
were exhibiting signs of venous congestion postoperatively
(See Table 1). In free-tissue transfers, there was a 100%
Figure 1. Indications for treatment with leeches (July 2004–July
2008). DIEP5Deep Inferior Epigastric artery Perforator. [Color
ﬁgure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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loss despite the use of leeches in all four cases of venous
congestion (See Table 1).
The number of leeches to be used depends on the
volume of the congested tissue. On a digital replant, for
example, two leeches are sufﬁcient, whereas larger
pedicled ﬂaps may need as many as ﬁve or six leeches.
Over the period from 2004 to 2008, there was a gradual
increasing trend in the use of leeches from 2004 to 2006,
peaking at 858 leeches in 2006 with a return to 330 and
457 leeches for 2007 and 2008, respectively. Over this
time period, the cost of leeches was stable at £11.54 per
leech giving a collective peak cost of £9221 in 2006.
DISCUSSION
Indications
Leeches are widely used by plastic, maxillofacial, and
other reconstructive surgeons to aid salvage of a variety of
Figure 2. Data regarding leech therapy from July 2004–July 2008). a: Start of leech therapy, b: length of leech therapy, c: blood transfusion require-
ments, and d: outcomes following leech therapy. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Table 1. Leech Therapy for Venous Congestion Following Reconstructive Surgery in 35 Patients (July 2004–July 2008)
Leech application with
prophylactic antibiotics (cases)
Leech application without
prophylactic antibiotics (cases)
Clinical problems Traumatic complete or partial amputation 5 6
Open fracture and wound breakdown 3 –
Tumor resection 6 6
Degloving or crush injury – 6
Other 2 1
Reconstructive
solution
Replantation and revascularization 5 9
Pedicled ﬂap 9 8
Free ﬂap 1 3
Clinical
infection
Anaerobes and/or Aeromonas spp. and/or MRSA 1 2
Aeromonas hydroph, Corynebacterium spp 1 –
Pseudomonas spp – 1
Staphylococcus aureus and Aeromonas spp. – 1
Enterococcus fecalis, Aeromonas spp.,
Morganella, morgagni, streptococcus
– 1
Flap survival 100% 4 10
>80% 6 1
50–79% 2 –
<50% – 1
0% 4 7
Patient factors and demographics, antibiotic prophylaxis, prevalence of infection, microbiology results, and salvage rates are listed.
Medicinal Leeches and the Microsurgeon 283
Microsurgery DOI 10.1002/micr
venously congested tissues. The two most common indica-
tions for leech use in this series included cutaneous pedicled
ﬂaps, ﬁrst described by Derganc and Zdravic2; and replanta-
tions, which Foucher so clearly deﬁned in 1981.23 For these
indications, with appropriate antibiotic prophylaxis, we
believe leeches should always be considered in the absence
of the relative contraindications outlined below.
Tamai,24 when reporting on his 20-year experience of
over 290 replantations, stated that there was only a 17% sal-
vage rate in replanted digits exhibiting venous congestion
postoperatively. He never used leeches. Foucher et al., when
using leeches routinely, recorded an overall salvage rate of
55–60 percent.23 These ﬁgures are comparable to our ﬁgures
(70%) (See Table 1). The unsuccessful replants tended to be
those with either a crush component to the initial soft tissue
injury or degloving injuries. Although it is impossible to
prove beyond doubt, in our clinical opinion, without the use
of leeches, some of these replants would have failed.
The salvage rate of our pedicled cutaneous ﬂaps
(77%) was comparable with the salvage rate of 70%
described by Derganc and Zdravic2 in their seminal paper
on the subject.
Although we believe their clinical utility is beyond
doubt, leeches are not the answer for all postoperative
problems. This has proven to be the case mainly in the
treatment of congested free-tissue transfers. Our experi-
ence in using leeches on free Deep Inferior Epigastric
artery Perforator (DIEP) ﬂaps was poor. This further rein-
forces the notion that in free ﬂaps developing a problem
with venous drainage, the treatment of choice should be
re-exploration of the anastomosis if at all possible. In our
free ﬂap cases, this was not performed due to a combina-
tion of both patient and technical factors. Recent experi-
mental evidence suggests that venous supercharging by
using additional routes of venous drainage can have a
statistically signiﬁcant beneﬁt with a correlation shown
between the number of venous outﬂow routes and sur-
vival of free ﬂaps and reduction in the incidence of ve-
nous congestion.25,26 A recent retrospective review of
564 consecutive DIEP ﬂaps at a single institution showed
that the use of a secondary vein in the drainage of a
DIEP ﬂap can signiﬁcantly reduce the incidence of venous
congestion without any signiﬁcant effect on the incidence of
complete ﬂap failure and overall takebacks.27 They also
demonstrated that the use of a secondary vein does not
signiﬁcantly increase operative times. Although initial
results are promising, further large clinical studies are
needed to demonstrate the beneﬁts of venous supercharging
procedures in free-tissue transfers.
Relative Contraindications
These include arterial insufﬁciency, immuno-
suppression, patients with a bleeding diathesis, Jehovah’s
witnesses,28 those who have previously exhibited allergy
to leeches or their foreign proteins,29 and individuals
with a psychological aversion to the annelid’s use.22
Those with diabetes and smokers in particular should be
counselled on the theoretical increased risks of infection
and treatment failure.
Start of Treatment
Leech therapy was started in the ﬁrst 48 hours 91% of
the time. There was no relationship between the commence-
ment of leech therapy and outcome. It has been postulated
that leech therapy should be commenced at the earliest sign
of outﬂow compromise,22 although to our knowledge there
has been no deﬁnitive proof that a reasonable delay in appli-
cation affects outcome.
Length of Treatment
In our series, the average length of leech treatment
was 5.6 days (range 1–13 days). (See Fig. 2b) It is evident
that when leeches are the only source of venous outﬂow
leech treatment should be continued until inosculation
occurs. On the basis of experimental animal models, this
process needs 3 to 5 days; however, limited clinical data
suggests that 6 to 10 days are necessary.30 A previous
meta-analysis has quoted the average leech therapy to be
4.2 days.22
Number and Timing of Leech Application
In general, the volume of leeches used per plastic sur-
gery unit per unit time, and the number of leeches used
per patient reﬂects enormous diversity of opinion and
practice, and there is little in the literature studying this.
Over the period from 2004 to 2008, the use of leeches
peaked at 858 leeches in 2006 with a peak cost of £9221
per ﬁnancial year. It is unclear whether a reduction in the
number of leeches used would reduce the cost, infection
rates, and transfusion requirements while maintaining
clinical outcomes. There is little doubt that the cost of
‘‘leeching’’ is likely to be cheaper than additional revisio-
nal surgery necessary in the absence of leeching.
In our experience, leeches should be applied every 6
hours, as evidence from the literature shows that over
90% of passive bleeding occurs within 5 hours. This 6
hourly application time allows for feeding and passive
bleeding. A commonly asked question is how many
leeches to use and how often. There is no clarity in the
literature regarding this question, and a wide variety of
regimes have been used. It is impossible to assess accu-
rately the number of leeches used per patient and the tim-
ing of application, as this was not stringently logged on a
patient by patient basis. Greater numbers of leeches are
likely to require high-dependency unit admission, regular
hemoglobin checks and blood transfusions.
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Transfusion Requirements
Persistent and prolonged bleeding after the removal of
the leech has long been considered a complication. In
1819, White reported that a 2-year-old girl had died due
to excessive blood loss induced by a single leech.31
Although adverse events associated with blood trans-
fusions are improving, they still cause morbidity and
mortality in both adult32 and pediatric populations.33
In our experience, blood transfusions were necessary
in 12 cases (34%) [mean 5 2.8 units, range 2–5 units].
All four of the DIEP ﬂap patients required blood transfu-
sions and none of the replantations. Clearly, the need for
transfusion will depend on patients’ comorbidities and the
nature of the operative intervention; however, the use of
leeches certainly potentiates bleeding risk. As stated by
Lineweaver et al.,16 the application of leeches to replants
is a different situation to that of free-tissue transfers.
Restoring circulation in these tissues by exsanguinations
is likely to result in a prohibitive amount of blood loss.
To support this argument, 100% transfusion requirements
have been reported by Chepeha et al.34 in a small series
of head and neck free-tissue transfers salvaged with
leeches and intensively monitored in Michigan. These
patients required an average of 13 units (range 5–28
units). Transfusion requirements of up to 78 units have
been reported in some units.35 In his meta-analysis,
Chaplain suggested a 66% requirement for blood transfu-
sion (mean 5 4.4 units). Problematic bleeding in the ma-
jority of cases can be well controlled with direct pressure
and topical thrombin. It is sensible to keep a daily check
on the hemoglobin during leech therapy, particularly in
young children.36 Previous studies have shown that any
combination of anticoagulant therapy in addition to the
use of leeches leads to a substantial increase in the need
for blood transfusion.37
Infection
The plastic surgery community has been aware of the
infection risk associated with leech application since it
was ﬁrst reported in the British Medical Journal by Dick-
son,38 and, then 3 years later, when it was discussed by
Whitlock in the British Journal of Plastic Surgery.39
Since then, a high incidence of infection during and after
application of medicinal leeches has been widely reported
despite external decontamination. The exact incidence of
leech-associated infection associated with postoperative
use is difﬁcult to assess, with incidences ranging from
2.4% to 36.2% being reported in the literature.39,40
Despite several publications advocating prophylactic anti-
biotics to combat leech-borne infections,16,41 many units
either do not use antibiotic prophylaxis at all or continue
to use less effective agents.36
The leech bite, created by three jaws, each containing
60 to 100 pairs of cutting teeth, forms a characteristic
Y-shaped triradiate conformation 1 mm in diameter and up
to 1.5 mm in depth.42
The combination of local tissue damage, along with
contact between the oral and digestive tract ﬂora, and
the patient allows the potential for infection. Extensive
studies have been carried out on the surface, mouth, and
digestive-tract microbiota of leeches,8,41,43 which show
Aeromonas spp. to be prominent in the resident ﬂora.
The venous congestion in plastic surgery patients leads to
a localized area of immunocompromise that is more
susceptible to infection. The most common clinical pre-
sentation is of cellulitis44 and, in severe cases, extensive
tissue loss and septicemia has been reported.45 Aeromo-
nas seems to have an afﬁnity for muscle tissue, and is
capable of producing extensive proteolytic enzymes lead-
ing to a picture resembling clostridial myonecrosis with
gas production.46 The ability of Aeromonas to invade the
walls of blood vessels with resultant vasculitis, throm-
bosis, and hemorrhagic necrosis is of most concern to
microsurgeons.
Over the 4-year study period, there were seven cases
of infection post leech therapy. Our infection rate with
Aeromonas spp. was 14.2% (5/35), with a salvage rate of
60% (3/5) (See Table 1). This is a satisfactory salvage
rate considering the meta-analysis by de Chalain et al.22
reporting on a clinical series of replants, free and pedi-
cled ﬂaps. His study reported a drop in the salvage rate
of tissues from an expected 60–80% to 31.8% in infected
tissues. Most authors in this analysis reported a complete
loss of infected tissues. Aeromonas infections typically
require treatment with aggressive debridement and antibi-
otic therapy, and this practice was followed in our series.
Seminal microbiological studies by Lineweaver et al.41,47
show that in patients receiving prophylactic quinolones,
there were signiﬁcant decreases in leech enteric bacterial
cultures.
In our clinical series, the proportion of patients
becoming infected after leech therapy was signiﬁcantly
greater in the group of patients that did not receive a
prophylactic antibiotic treatment (Fisher’s exact test P 5
0.0005).
Despite the emerging evidence, high levels of
resistance to ﬁrst generation cephalosporins, penicillins
(via b-lactamases), tetracyclines, and augmentin have
been observed in studies,48 with ﬂuoroquinoles seeming
to be consistently active.49 Even new and widely used
textbooks50 continue to advocate the use of potentially
ineffective agents such as amoxicillin and clavulanic
acid preparations (co-amoxiclav). Our experience and
those of others suggest that prophylactic ﬂuoroquino-
lones seem to be mandatory given the preponderance of
infection.
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CONCLUSION
Despite the widespread use of leeches worldwide, we
believe that there are insufﬁcient prospective studies with
large enough numbers to inform the microsurgical spe-
cialist on outcomes from leech usage and the risks and
beneﬁts for each indication. Our future research efforts
will involve an interdisciplinary prospective multicenter
study combining genetic clariﬁcation of leech types, hem-
atological parameters, outcome analysis, and isolates
from surgical wounds.
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